DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Dr. Michael Meighen is a physician who is board certified in Physiatry and Pain Medicine. He is the author of #1 Best Selling Book...
In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he...
Amir Baluch, MD, is an investor, serial entrepreneur, and fund manager at BioWise Capital. Dr. Baluch has ten years experience in private equity and...
